
The Food and Drug Administration (FDA) is moving ahead with a safety review of the abortion pill mifepristone, according to an administration official. The move marks a victory for anti-abortion groups that could pave the way for the Trump administration to restrict its use and how it can be distributed. The retrospective analysis of data…
View original source — The Hill ↗
